HVEM Antibody (122): sc-57195

HVEM Antibody (122) is a mouse monoclonal IgG1 antibody that detects HVEM (herpes virus entry mediator A) in human samples through applications such as immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). HVEM, also known as TR2, ATAR, HVEA, LIGHTR, or TNFRSF14, is a 283 amino acid single-pass type I membrane protein predominantly expressed in the lung, spleen, and thymus. As a member of the tumor necrosis factor receptor superfamily, HVEM plays a pivotal role in the entry of herpes simplex virus (HSV) types 1 and 2 into T lymphocytes by acting as a receptor for the viral envelope glycoprotein D (gD). Additionally, HVEM interacts with two important cellular ligands, secreted lymphotoxin and LIGHT, the latter being a member of the TNF superfamily produced by activated T-cells, which is implicated in inducing apoptosis and suppressing tumor formation. The structure of HVEM, characterized by three TNFR-Cys repeats, is crucial for mediating viral entry and modulating immune responses, highlighting HVEM′s significance in both viral pathogenesis and potential therapeutic applications. HVEM is encoded by a gene located on human chromosome 1, which spans 260 million base pairs and contains over 3,000 genes, representing nearly 8% of the human genome. Anti-HVEM antibody (122) is an essential tool for researchers studying the intricate mechanisms of viral infections and immune regulation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HVEM Antibody (122) References:

1. LIGHT-HVEM signaling and the regulation of T cell-mediated immunity.  |  Granger, SW. and Rickert, S. 2003. Cytokine Growth Factor Rev. 14: 289-96. PMID: 12787566
2. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.  |  del Rio, ML., et al. 2010. J Leukoc Biol. 87: 223-35. PMID: 20007250
3. Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling.  |  Shui, JW., et al. 2011. J Leukoc Biol. 89: 517-23. PMID: 21106644
4. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.  |  Pasero, C., et al. 2012. Curr Opin Pharmacol. 12: 478-85. PMID: 22445654
5. HVEM: An unusual TNF receptor family member important for mucosal innate immune responses to microbes.  |  Shui, JW. and Kronenberg, M. 2013. Gut Microbes. 4: 146-51. PMID: 23333859
6. LIGHT/HVEM/LTβR interaction as a target for the modulation of the allogeneic immune response in transplantation.  |  del Rio, ML., et al. 2013. Am J Transplant. 13: 541-51. PMID: 23356438
7. The BTLA-HVEM-CD5 Immunoregulatory Axis-An Instructive Mechanism Governing pTreg Cell Differentiation.  |  Bourque, J. and Hawiger, D. 2019. Front Immunol. 10: 1163. PMID: 31191536
8. Binding of herpesvirus entry mediator (HVEM) and HSV-1 gD affect reactivation but not latency levels.  |  Jaggi, U., et al. 2023. PLoS Pathog. 19: e1011693. PMID: 37738264
9. Intraepithelial lymphocytes promote intestinal regeneration through CD160/HVEM signaling.  |  Huang, J., et al. 2024. Mucosal Immunol. 17: 257-271. PMID: 38340986
10. HVEM in acute lymphocytic leukemia facilitates tumour immune escape by inhibiting CD8+ T cell function.  |  Liu, Y., et al. 2024. Cell Oncol (Dordr). 47: 1779-1796. PMID: 38809326

The preferred HVEM antibody is HVEM Antibody (D-5): sc-365971.